Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of two amino acids, l-ornithine and l-aspartate, used in the management of hepatic encephalopathy. It is believed to reduce ammonia levels by promoting its detoxification in the liver and peripheral tissues.
## Primary Indications
* Management of overt hepatic encephalopathy.
* Adjunctive treatment in hyperammonemia.
## Adult Dosing
**Oral:**
* Typically 3 to 6 grams of l-ornithine l-aspartate, divided into 3 doses per day.
* Maximum daily dose is generally not well-defined but may approach 18 grams or more in severe cases, depending on local protocol and patient response.
**Intravenous:**
* Typically 5 grams of l-ornithine l-aspartate, administered twice daily as an infusion.
* Dosing can be adjusted based on the severity of encephalopathy and ammonia levels.
* Maximum daily dose for IV administration is generally 10 grams, but may be higher in specific protocols.
## Pediatric Dosing
There is limited established pediatric dosing for Hepamerz. Use is generally based on expert opinion and extreme caution. Available data is insufficient to provide specific dose recommendations.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is used in the context of liver dysfunction. However, careful monitoring of ammonia levels and clinical status is crucial in these patients.
## Contraindications
* Known hypersensitivity to l-ornithine or l-aspartate.
* Severe renal impairment (creatinine clearance generally <25 mL/min) due to potential accumulation of amino acids.
* Certain metabolic disorders that affect amino acid metabolism.
## Adverse Effects
Common adverse effects include:
* Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort.
* Rarely, hypersensitivity reactions.
* Electrolyte imbalances may occur, especially with excessive intake or prolonged use.
## Key Drug Interactions
* No significant drug interactions are well-documented. However, caution should be exercised when co-administering with other medications affecting ammonia levels or amino acid metabolism.
## Monitoring
* Serum ammonia levels.
* Clinical signs and symptoms of hepatic encephalopathy (e.g., altered mental status, asterixis).
* Renal function (creatinine, BUN).
* Electrolytes.
## Clinical Pearls
* Hepamerz is often used as an adjunct to other treatments for hepatic encephalopathy.
* The oral formulation may have a delayed onset of action compared to IV.
* It is important to assess the underlying cause of hyperammonemia and hepatic encephalopathy.
* Dosing should be individualized based on patient response and tolerance.
---
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature before making clinical decisions. Dosing and recommendations may vary based on local guidelines and patient-specific factors.*
